| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| P Lemmens, M Brecher, B Van Baele. A combined analysis of double-blind studies with risperidone vs. placebo and other antipsychotic agents: factors associated with extrapyramidal symptoms. Acta psychiatrica Scandinavica. vol 99. issue 3. 1999-06-23. PMID:10100910. |
combined data from double-blind risperidone studies were used to analyse the severity of extrapyramidal symptoms (eps) associated with treatment in patients with chronic schizophrenia. |
1999-06-23 |
2023-08-12 |
Not clear |
| A L Morera, P Barreiro, J L Cano-Muño. Risperidone and clozapine combination for the treatment of refractory schizophrenia. Acta psychiatrica Scandinavica. vol 99. issue 4. 1999-06-01. PMID:10223435. |
risperidone and clozapine combination for the treatment of refractory schizophrenia. |
1999-06-01 |
2023-08-12 |
Not clear |
| S Leucht, G Pitschel-Walz, D Abraham, W Kisslin. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophrenia research. vol 35. issue 1. 1999-05-27. PMID:9988841. |
the objective of this meta-analysis is to summarize the efficacy and tolerability of the new antipsychotics risperidone, olanzapine, sertindole and quetiapine in schizophrenia compared to placebo and conventional antipsychotics. |
1999-05-27 |
2023-08-12 |
Not clear |
| N Takahashi, T Terao, T Oga, M Okad. Comparison of risperidone and mosapramine addition to neuroleptic treatment in chronic schizophrenia. Neuropsychobiology. vol 39. issue 2. 1999-05-19. PMID:10072664. |
comparison of risperidone and mosapramine addition to neuroleptic treatment in chronic schizophrenia. |
1999-05-19 |
2023-08-12 |
Not clear |
| N Takahashi, T Terao, T Oga, M Okad. Comparison of risperidone and mosapramine addition to neuroleptic treatment in chronic schizophrenia. Neuropsychobiology. vol 39. issue 2. 1999-05-19. PMID:10072664. |
there is little information regarding the effects of risperidone addition to neuroleptic treatment in chronic schizophrenia. |
1999-05-19 |
2023-08-12 |
Not clear |
| N Takahashi, T Terao, T Oga, M Okad. Comparison of risperidone and mosapramine addition to neuroleptic treatment in chronic schizophrenia. Neuropsychobiology. vol 39. issue 2. 1999-05-19. PMID:10072664. |
although both additions resulted in significant, albeit modest, improvement, there was no significant difference in the scores on the positive and negative syndrome scale for schizophrenia between risperidone and mosapramine addition. |
1999-05-19 |
2023-08-12 |
Not clear |
| M J Schiller, M Shumway, W A Hargreave. Treatment costs and patient outcomes with use of risperidone in a public mental health setting. Psychiatric services (Washington, D.C.). vol 50. issue 2. 1999-05-17. PMID:10030481. |
risperidone's effectiveness in reducing symptoms and its cost were compared with the effectiveness and cost of standard antipsychotic medication among matched groups of outpatients with schizophrenia. |
1999-05-17 |
2023-08-12 |
Not clear |
| J Fang, M Bourin, G B Bake. Metabolism of risperidone to 9-hydroxyrisperidone by human cytochromes P450 2D6 and 3A4. Naunyn-Schmiedeberg's archives of pharmacology. vol 359. issue 2. 1999-04-20. PMID:10048600. |
risperidone is a relatively new antipsychotic drug that has been reported to improve both the positive and the negative symptoms of schizophrenia and produces relatively few extrapyramidal side effects at low doses. |
1999-04-20 |
2023-08-12 |
human |
| D L Kleinberg, J M Davis, R de Coster, B Van Baelen, M Breche. Prolactin levels and adverse events in patients treated with risperidone. Journal of clinical psychopharmacology. vol 19. issue 1. 1999-04-07. PMID:9934944. |
all data from randomized, double-blind studies of risperidone in patients with chronic schizophrenia were analyzed. |
1999-04-07 |
2023-08-12 |
Not clear |
| S Kaspe. Risperidone and olanzapine: optimal dosing for efficacy and tolerability in patients with schizophrenia. International clinical psychopharmacology. vol 13. issue 6. 1999-03-29. PMID:9861575. |
risperidone and olanzapine: optimal dosing for efficacy and tolerability in patients with schizophrenia. |
1999-03-29 |
2023-08-12 |
Not clear |
| G Chouinard, L Kopala, A Labelle, L Beauclair, S V Johnson, K I Sing. Phase-IV multicentre clinical study of risperidone in the treatment of outpatients with schizophrenia. The RIS-CAN-3 Study Group. Canadian journal of psychiatry. Revue canadienne de psychiatrie. vol 43. issue 10. 1999-03-18. PMID:9868567. |
phase-iv multicentre clinical study of risperidone in the treatment of outpatients with schizophrenia. |
1999-03-18 |
2023-08-12 |
Not clear |
| G Chouinard, L Kopala, A Labelle, L Beauclair, S V Johnson, K I Sing. Phase-IV multicentre clinical study of risperidone in the treatment of outpatients with schizophrenia. The RIS-CAN-3 Study Group. Canadian journal of psychiatry. Revue canadienne de psychiatrie. vol 43. issue 10. 1999-03-18. PMID:9868567. |
since most clinical trials of atypical antipsychotics have been conducted in hospitalized patients, a phase-iv, multicentre, 8-week, open-label, flexible-dose study was performed to assess the efficacy and safety of risperidone in outpatients with schizophrenia. |
1999-03-18 |
2023-08-12 |
Not clear |
| R Mahmoud, L Engelhart, D Ollendorf, G Oste. The Risperidone Outcomes Study of Effectiveness (ROSE): a model for evaluating treatment strategies in typical psychiatric practice. The Journal of clinical psychiatry. vol 60 Suppl 3. 1999-03-15. PMID:10073377. |
we describe the design of a multicenter, randomized clinical trial to compare clinical, quality-of-life, and economic outcomes in patients with schizophrenia or schizoaffective disorder who were treated with risperidone or any of 13 conventional antipsychotic drugs approved for use in the united states. |
1999-03-15 |
2023-08-12 |
Not clear |
| S Kapur, R B Zipursky, G Remingto. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. The American journal of psychiatry. vol 156. issue 2. 1999-02-25. PMID:9989565. |
clinical and theoretical implications of 5-ht2 and d2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. |
1999-02-25 |
2023-08-12 |
Not clear |
| A F Breier, A K Malhotra, T P Su, D A Pinals, I Elman, C M Adler, R T Lafargue, A Clifton, D Picka. Clozapine and risperidone in chronic schizophrenia: effects on symptoms, parkinsonian side effects, and neuroendocrine response. The American journal of psychiatry. vol 156. issue 2. 1999-02-25. PMID:9989566. |
clozapine and risperidone in chronic schizophrenia: effects on symptoms, parkinsonian side effects, and neuroendocrine response. |
1999-02-25 |
2023-08-12 |
Not clear |
| A F Breier, A K Malhotra, T P Su, D A Pinals, I Elman, C M Adler, R T Lafargue, A Clifton, D Picka. Clozapine and risperidone in chronic schizophrenia: effects on symptoms, parkinsonian side effects, and neuroendocrine response. The American journal of psychiatry. vol 156. issue 2. 1999-02-25. PMID:9989566. |
clozapine and risperidone were the first two "second-generation" antipsychotic drugs approved for schizophrenia. |
1999-02-25 |
2023-08-12 |
Not clear |
| Y Melamed, D Mazeh, A Elizu. Risperidone treatment for a patient suffering from schizophrenia and IDDM. Canadian journal of psychiatry. Revue canadienne de psychiatrie. vol 43. issue 9. 1999-02-22. PMID:9825172. |
risperidone treatment for a patient suffering from schizophrenia and iddm. |
1999-02-22 |
2023-08-12 |
Not clear |
| M J Travis, G F Busatto, L S Pilowsky, R Mulligan, P D Acton, S Gacinovic, J Mertens, D Terrière, D C Costa, P J Ell, R W Kerwi. 5-HT2A receptor blockade in patients with schizophrenia treated with risperidone or clozapine. A SPET study using the novel 5-HT2A ligand 123I-5-I-R-91150. The British journal of psychiatry : the journal of mental science. vol 173. 1999-02-09. PMID:9926100. |
5-ht2a receptor blockade in patients with schizophrenia treated with risperidone or clozapine. |
1999-02-09 |
2023-08-12 |
Not clear |
| R S Kern, M F Green, B D Marshall, W C Wirshing, D Wirshing, S McGurk, S R Marder, J Mint. Risperidone vs. haloperidol on reaction time, manual dexterity, and motor learning in treatment-resistant schizophrenia patients. Biological psychiatry. vol 44. issue 8. 1999-01-29. PMID:9798076. |
risperidone vs. haloperidol on reaction time, manual dexterity, and motor learning in treatment-resistant schizophrenia patients. |
1999-01-29 |
2023-08-12 |
Not clear |
| R S Kern, M F Green, B D Marshall, W C Wirshing, D Wirshing, S McGurk, S R Marder, J Mint. Risperidone vs. haloperidol on reaction time, manual dexterity, and motor learning in treatment-resistant schizophrenia patients. Biological psychiatry. vol 44. issue 8. 1999-01-29. PMID:9798076. |
the present study compared the effects of risperidone vs. haloperidol on reaction time, manual dexterity, and two types of motor learning in a sample of treatment-resistant schizophrenia patients. |
1999-01-29 |
2023-08-12 |
Not clear |